-
Something wrong with this record ?
The zymogenic form of SARS-CoV-2 main protease: A discrete target for drug discovery
P. Novotný, J. Humpolíčková, V. Nováková, S. Stanchev, K. Stříšovský, M. Zgarbová, J. Weber, R. Kryštůfek, J. Starková, M. Hradilek, A. Moravcová, J. Günterová, K. Bach, P. Majer, J. Konvalinka, T. Majerová
Language English Country United States
Document type Journal Article
NLK
Directory of Open Access Journals
from 2021
PubMed Central
from 2005
Open Access Digital Library
from 1905-10-01
Open Access Digital Library
from 1905-10-01
ROAD: Directory of Open Access Scholarly Resources
from 1905
- MeSH
- Antiviral Agents * pharmacology chemistry MeSH
- COVID-19 Drug Treatment MeSH
- HEK293 Cells MeSH
- Protease Inhibitors pharmacology chemistry MeSH
- Coronavirus 3C Proteases * metabolism antagonists & inhibitors chemistry genetics MeSH
- Humans MeSH
- Mutation MeSH
- Drug Discovery * methods MeSH
- Proteolysis MeSH
- SARS-CoV-2 * enzymology drug effects metabolism genetics MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro) autocatalytically releases itself out of the viral polyprotein to form a fully active mature dimer in a manner that is not fully understood. Here, we introduce several tools to help elucidate differences between cis (intramolecular) and trans (intermolecular) proteolytic processing and to evaluate inhibition of precursor Mpro. We found that many mutations at the P1 position of the N-terminal autoprocessing site do not block cis autoprocessing but do inhibit trans processing. Notably, substituting the WT glutamine at the P1 position with isoleucine retains Mpro in an unprocessed precursor form that can be purified and further studied. We also developed a cell-based reporter assay suitable for compound library screening and evaluation in HEK293T cells. This assay can detect both overall Mpro inhibition and the fraction of uncleaved precursor form of Mpro through separable fluorescent signals. We observed that inhibitory compounds preferentially block mature Mpro. Bofutrelvir and a novel compound designed in-house showed the lowest selectivity between precursor and mature Mpro, indicating that inhibition of both forms may be possible. Additionally, we observed positive modulation of precursor activity at low concentrations of inhibitors. Our findings help expand understanding of the SARS-CoV-2 viral life cycle and may facilitate development of strategies to target precursor form of Mpro for inhibition or premature activation of Mpro.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25010440
- 003
- CZ-PrNML
- 005
- 20250429134649.0
- 007
- ta
- 008
- 250415s2025 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jbc.2024.108079 $2 doi
- 035 __
- $a (PubMed)39675720
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Novotný, Pavel $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic; Faculty of Science, Department of Physical and Macromolecular Chemistry, Charles University in Prague, Prague, Czech Republic
- 245 14
- $a The zymogenic form of SARS-CoV-2 main protease: A discrete target for drug discovery / $c P. Novotný, J. Humpolíčková, V. Nováková, S. Stanchev, K. Stříšovský, M. Zgarbová, J. Weber, R. Kryštůfek, J. Starková, M. Hradilek, A. Moravcová, J. Günterová, K. Bach, P. Majer, J. Konvalinka, T. Majerová
- 520 9_
- $a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro) autocatalytically releases itself out of the viral polyprotein to form a fully active mature dimer in a manner that is not fully understood. Here, we introduce several tools to help elucidate differences between cis (intramolecular) and trans (intermolecular) proteolytic processing and to evaluate inhibition of precursor Mpro. We found that many mutations at the P1 position of the N-terminal autoprocessing site do not block cis autoprocessing but do inhibit trans processing. Notably, substituting the WT glutamine at the P1 position with isoleucine retains Mpro in an unprocessed precursor form that can be purified and further studied. We also developed a cell-based reporter assay suitable for compound library screening and evaluation in HEK293T cells. This assay can detect both overall Mpro inhibition and the fraction of uncleaved precursor form of Mpro through separable fluorescent signals. We observed that inhibitory compounds preferentially block mature Mpro. Bofutrelvir and a novel compound designed in-house showed the lowest selectivity between precursor and mature Mpro, indicating that inhibition of both forms may be possible. Additionally, we observed positive modulation of precursor activity at low concentrations of inhibitors. Our findings help expand understanding of the SARS-CoV-2 viral life cycle and may facilitate development of strategies to target precursor form of Mpro for inhibition or premature activation of Mpro.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a SARS-CoV-2 $x enzymologie $x účinky léků $x metabolismus $x genetika $7 D000086402
- 650 _2
- $a HEK293 buňky $7 D057809
- 650 12
- $a objevování léků $x metody $7 D055808
- 650 12
- $a koronavirové proteasy 3C $x metabolismus $x antagonisté a inhibitory $x chemie $x genetika $7 D000086782
- 650 12
- $a antivirové látky $x farmakologie $x chemie $7 D000998
- 650 _2
- $a inhibitory proteas $x farmakologie $x chemie $7 D011480
- 650 _2
- $a farmakoterapie COVID-19 $7 D000093485
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a proteolýza $7 D059748
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Humpolíčková, Jana $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Nováková, Veronika $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic; Faculty of Science, Department of Genetics and Microbiology, Charles University in Prague, Prague, Czech Republic
- 700 1_
- $a Stanchev, Stancho $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Stříšovský, Kvido $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Zgarbová, Michala $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic; Faculty of Science, Department of Genetics and Microbiology, Charles University in Prague, Prague, Czech Republic
- 700 1_
- $a Weber, Jan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Kryštůfek, Robin $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic; Faculty of Science, Department of Physical and Macromolecular Chemistry, Charles University in Prague, Prague, Czech Republic
- 700 1_
- $a Starková, Jana $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Hradilek, Martin $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Moravcová, Adéla $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic; Department of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Prague, Czech Republic
- 700 1_
- $a Günterová, Jana $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Bach, Kathrin $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic; Faculty of Science, Department of Genetics and Microbiology, Charles University in Prague, Prague, Czech Republic
- 700 1_
- $a Majer, Pavel $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Konvalinka, Jan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic; Faculty of Science, Department of Biochemistry, Charles University in Prague, Prague, Czech Republic
- 700 1_
- $a Majerová, Taťána $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic. Electronic address: tatana.majerova@uochb.cas.cz
- 773 0_
- $w MED00002546 $t The Journal of biological chemistry $x 1083-351X $g Roč. 301, č. 1 (2025), s. 108079
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39675720 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429134645 $b ABA008
- 999 __
- $a ok $b bmc $g 2311661 $s 1247521
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 301 $c 1 $d 108079 $e 20241214 $i 1083-351X $m The Journal of biological chemistry $n J Biol Chem $x MED00002546
- LZP __
- $a Pubmed-20250415
